...
PTCTMID

PTC Therapeutics, Inc.

HealthcareBiotechnology
$68.19
$0.00(+0.13%)
52W$35.95
$87.50
FinancialsValuationvs AGIO
Updated Mar 3, 12:00 AM
RSI35
RS Rating63/99
Beta0.91
Volatility49%
F-Score4/9
Mkt Cap$5.5B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

PTC Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 63), indicating performance broadly in line with the market. Earnings growth of 114% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
63
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.91
vs S&P 500
MARKET
52W Position
63%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$74.36
50 SMA > 100 SMA$73.42
100 SMA > 150 SMA$67.11
150 SMA > 200 SMA$62.52

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$71.35-4.43%BELOW
50 SMA$74.36-8.29%BELOW
100 SMA$73.42-7.12%BELOW
150 SMA$67.11+1.60%ABOVE
200 SMA$62.52+9.07%ABOVE

Price Performance

1D+0.1%
1W-3.3%
1M-9.8%
3M-20.7%
6M+37.0%
YTD-11.1%
1Y+23.4%
3Y+16.0%
52-Week Trading Range63% from low
$68.19
52W Low$35.95
52W High$87.50

Technical Indicators

RSI (14)BEARISH
35.0
305070
VCP ScoreCOOL
5/10
Base depth: 22.8%

Risk Profile

Beta
0.91
52W Vol
49%
ATR
$2.84
Max DD (1Y)
-37%

Volume Analysis

Today
68
50D Avg
993.8K
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q4'24+59%
$-0.85
Q1'25+937%
$10.04
Q2'25+36%
$-0.83
Q3'25+114%
$0.20
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+46.99%
5 Years:+35.37%
3 Years:+35.30%
TTM:+97.54%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+244.11%

Stock Price CAGR

10 Years:+23.93%
5 Years:+3.23%
3 Years:+16.01%
1 Year:+23.40%

Return on Equity

10Y Avg:-87.9%
5Y Avg:-216.7%
3Y Avg:—
Last Year:—

Key Metrics

Market Cap$5.5B
Gross Margin—
Net Margin39.4%
Piotroski F-Score4/9

More PTCT Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

PTCT vs AGIOAGIOVRTXASNDBBIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 63 meansPTCT outperformed 63% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.91 means 9% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is PTCT in an uptrend right now?

PTCT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is PTCT overbought or oversold?

PTCT's RSI (14) is 35. The stock is in neutral territory, neither overbought nor oversold.

Is PTCT outperforming the market?

PTCT has a Relative Strength (RS) Rating of 63 out of 99. PTCT is performing about average compared to the market.

Where is PTCT in its 52-week range?

PTCT is trading at $68.19, which is 78% of its 52-week high ($87.50) and 63% above its 52-week low ($35.95).

How volatile is PTCT?

PTCT has a Beta of 0.91 and 52-week volatility of 49%. It's less volatile than the S&P 500 - generally more stable.